

AUROBINDO PHARMA LIMITED
Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Unaudited Financial Results for the Quarter & Half year ended 30th September, 2010

(Rs.in lakhs)

Particulars	Stand alone					Consolidated				
	Three months ended		Six months ended		Year Ended	Three months ended		Six months ended		Year Ended
	30.09.2010	30.09.2009	30.09.2010	30.09.2009	31.03.2010	30.09.2010	30.09.2009	30.09.2010	30.09.2009	31.03.2010
	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Sales(including excise duty) & operating income	107,501	84,261	196,158	162,005	331,960	113,725	90,787	208,114	177,769	365,133
Less: Excise Duty	2,458	1,630	4,364	3,077	6,733	2,463	2,523	4,627	4,229	7,590
Net Sales	105,043	82,631	191,794	158,928	325,227	111,262	88,264	203,487	173,540	357,543
Expenditure										
a. (Increase)/Decrease in Stock	(2,037)	(1,974)	(1,174)	(2,577)	(14,748)	(3,215)	(2,523)	(3,189)	(3,541)	(18,492)
b. Material Consumed	56,691	44,629	103,550	87,176	187,775	55,364	41,242	98,629	81,373	177,927
c. Purchase of traded goods	176	924	292	1,271	1,936	3,327	3,454	5,891	6,480	12,673
d. Staff Cost	7,358	5,339	14,260	10,405	23,262	10,737	7,866	20,586	14,772	32,728
e. Depreciation/ Amortisation	3,145	2,396	5,884	4,546	9,546	4,071	3,696	8,078	7,022	14,934
f. Other Expenditure	16,124	13,044	30,990	25,077	52,046	19,627	17,525	38,975	34,186	70,389
Total Expenditure	81,457	64,358	153,802	125,898	259,817	89,911	71,260	168,970	140,292	290,159
Profit from Operations before Other Income, interest, tax & exceptional income	23,586	18,273	37,992	33,030	65,410	21,351	17,004	34,517	33,248	67,384
Other Income	261	1,089	391	1,225	2,281	1,058	1,270	1,369	1,493	3,894
Profit before interest, tax & exceptional item	23,847	19,362	38,383	34,255	67,691	22,409	18,274	35,886	34,741	71,278
Interest (net)	1,571	1,344	2,480	3,125	5,233	1,927	1,819	3,219	4,087	6,779
Foreign Exchange (Gain)/ Loss (net)	(6,351)	(554)	(1,849)	(3,358)	(8,558)	(7,619)	356	(3,442)	(5,399)	(10,726)
Profit from Ordinary Activities before tax & exceptional item	28,627	18,572	37,752	34,488	71,016	28,101	16,099	36,109	36,053	75,225
Provision for Taxation	7,224	5,742	10,015	9,047	18,659	8,297	5,778	11,148	9,087	19,136
Profit before Exceptional item & Minority Interest	21,403	12,830	27,737	25,441	52,357	19,804	10,321	24,961	26,966	56,089
Exceptional item (Net of tax)	-	-	-	-	219	-	-	-	-	219
Profit before Minority Interest	21,403	12,830	27,737	25,441	52,576	19,804	10,321	24,961	26,966	56,308
Minority Interest	-	-	-	-	-	(28)	2	(21)	(11)	(32)
Net Profit	21,403	12,830	27,737	25,441	52,576	19,832	10,319	24,982	26,977	56,340
Paid-up Equity Share Capital (Face value Rs. 5/- per share)	2,911	2,688	2,911	2,688	2,786	2,911	2,688	2,911	2,688	2,786
Reserves excluding Revaluation Reserve					188,651					180,122
Basic Earnings per share before & after Extraordinary items (Rs.) (not annualised)	37.09	23.86	48.72	47.32	97.09	34.37	19.19	43.88	50.18	104.04
Diluted Earnings per share before & after Extraordinary items (Rs.) (not annualised)	33.37	19.84	43.78	39.35	83.16	30.92	15.96	39.43	41.73	89.12
Public Shareholding										
- Number of Shares	26,530,301	22,049,529	26,530,301	22,049,529	24,027,998					
- Percentage of Shareholding	45.57	41.01	45.57	41.01	43.12					
Promoters and promoter group Shareholding										
a) Pledged/ Encumbered										
- Number of Shares	6,767,721	10,139,000	6,767,721	10,139,000	6,792,721					
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	21.36	31.97	21.36	31.97	21.43					
- Percentage of Shares (as a % of the total share capital of the company)	11.62	18.86	11.62	18.86	12.19					
b) Non-encumbered										
- Number of Shares	24,923,536	21,576,739	24,923,536	21,576,739	24,908,118					
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	78.64	68.03	78.64	68.03	78.57					
- Percentage of Shares (as a % of the total share capital of the company)	42.81	40.13	42.81	40.13	44.69					



STATEMENT OF ASSETS & LIABILITIES


(Rs. In lakhs)

Particulars	Stand alone		Consolidated	
	As at 30-09-2010	As at 31-03-2010	As at 30-09-2010	As at 31-03-2010
	Unaudited	Audited	Unaudited	Audited
SHAREHOLDERS FUNDS:				
(a) Capital	2,911	2,786	2,911	2,786
(b) Reserves and Surplus	225,787	188,651	215,059	180,122
LOAN FUNDS	206,196	194,478	224,160	215,457
MINORITY INTEREST	-	-	549	433
DEFERRED TAX LIABILITY (Net)	10,354	9,507	9,964	9,118
TOTAL	445,248	395,422	452,643	407,916
FIXED ASSETS (Net) including Capital Work in progress	171,393	154,481	252,054	228,093
INVESTMENTS	45,599	37,091	29	28
CURRENT ASSETS, LOANS AND ADVANCES:				
(a) Inventories	104,806	94,482	122,268	110,245
(b) Sundry Debtors	136,311	115,135	112,027	95,601
(c) Cash and Bank balances	2,023	456	9,441	7,283
(d) Other current assets	788	466	788	334
(e) Loans and Advances	54,448	57,298	38,780	37,131
Less: Current Liabilities and Provisions				
(a) Liabilities	(64,531)	(60,883)	(75,550)	(67,280)
(b) Provisions	(5,589)	(3,104)	(7,194)	(3,519)
Net Current Assets	228,256	203,850	200,560	179,795
MISCELLANEOUS EXPENDITURE (Not written off or adjusted)	-	-	-	-
PROFIT AND LOSS ACCOUNT	-	-	-	-
TOTAL	445,248	395,422	452,643	407,916

NOTES:

- The above unaudited financial results were reviewed by the Audit Committee and have been approved by the Board at its meeting held on November 3, 2010. A Limited Review of the above stand alone financial results has been carried out by the Statutory Auditors.
- The Consolidated financial results, which are optional, have been presented by the Company, so as to provide additional information.
- The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement', AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all subsidiaries and Joint Ventures.
- The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- Investor complaints pending at the beginning of the quarter: Nil, received: 61, resolved: 61 and lying unresolved at the end of the quarter: Nil.
- Sales for the quarter include exports of Rs.74,275 lakhs (Rs.55,757 lakhs). Stand alone sales also include dossier income of Rs. 4,784 lakhs (Rs.3,913 lakhs) and Consolidated sales include dossier income of Rs.6,988 lakhs (Rs.4,024 lakhs).
- Foreign Exchange (Gain)/Loss represents exchange differences arising on all foreign currency transactions. This includes gain during the quarter due to restatement of Foreign Currency Convertible Bonds (net of Deposits) Rs.2,102 lakhs (Loss of Rs.367 lakhs).
- In respect of matters referred to in the limited review report by the Auditors for the quarter ended June 30, 2010 and September 30, 2010 relating to non-provision of premium on redemption of outstanding USD 139.20 Million Zero Coupon Foreign Currency Convertible Bonds (FCCBs), the management is of the opinion that it is contingent in nature, as the determination and crystallisation of liability is dependent upon the outcome of uncertain future events or actions, not wholly within the control of the Company.
- The paid up share capital of the Company has increased during July-September 2010 to Rs. 2911.08 lakhs. This is due to allotment of 1,741,394 Equity Shares of Rs.5/- each for cash at premium of Rs. 517.036 upon request received for conversion of FCCBs worth USD 20.95 million, out of USD 60 million issue in terms of the offer document, and allotment of 27,007 Equity shares of Rs.5/- each at a premium of Rs. 357.60 per under ESOP 2004 Scheme by the Compensation Committee of the Company at their meeting held on July 19, 2010.
- The outstanding FCCBs worth USD 2,118,000 (forming part of USD 60 Million issue) were redeemed on due date i.e. August 11, 2010.
- During the quarter, the Company has incorporated new step down subsidiaries viz., Aurobindo Pharma (Singapore) Pte Limited in Singapore and Aurobindo Pharma BV in Netherlands.
- Aurobindo Pharma Aps, Denmark, a step down subsidiary has been liquidated effective September 16, 2010.
- The Company has presented for the first time the "Statement of Assets and Liabilities" as on September 30, 2010 in accordance with amendment of clause 41 to the listing agreement effective April 2010 and as such disclosure of Statement of Assets and liabilities as on September 30, 2009 has not been made.
- The Board in its meeting held on November 3, 2010 has approved an interim dividend of 100% i.e Rs.5/- per equity share of Rs.5/- each. Consequently, the amount of interim dividend would be Rs. 2,911.08 lakhs
- The Board in its meeting held on November 3, 2010, has approved the sub-division of equity shares of the face value of Rs. 5/- each in the Company into equity shares of the face value of Rs.1/- each. The sub-division would be subject to the approval of the shareholders and such other approvals as may be necessary.
- Figures for the previous periods/year have been rearranged/regrouped wherever necessary.

By Order of the Board


K.Nithyananda Reddy
Managing Director

Place: Hyderabad

Date: November 3, 2010

www.aurobindo.com

Limited Review Report

**Review Report to
The Board of Directors
Aurobindo Pharma Limited**

1. We have reviewed the accompanying statement of unaudited unconsolidated financial results of Aurobindo Pharma Limited ('the Company') for the quarter ended September 30, 2010 (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Without qualifying our opinion, we draw attention in respect to non-provision of premium for the quarter ended September 30, 2010 amounting to Rs. 3,575.80 lakhs payable on 139,200 Zero Coupon Foreign Currency Convertible Bonds of USD 1000 each issued by the Company. The cumulative amount of premium as at September 30, 2010 is Rs. 28,334.09 lakhs. Management is of the view that the liability to pay premium on redemption is contingent and the ultimate outcome of the matter cannot be presently determined. Accordingly, no provision has been made in the accompanying statement of unaudited unconsolidated financial results for the liability, if any, that may accrue in the event of redemption.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited unconsolidated financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting", [notified pursuant to the Companies (Accounting Standards) Rules, 2006, (as amended)] and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

S. R. Batliboi & Associates
For S.R. BATLIBOI & ASSOCIATES
Firm registration number: 101049W
Chartered Accountants


per Vikas Kumar Pansari
Partner
Membership No.: 93649
Place: Hyderabad
Date: November 3, 2010

